Material Agreement Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

Effective August 1, 2024, Propanc Biopharma, Inc. (the "Company") entered into and closed a loan agreement (the "Loan") with an investor, pursuant to which the investor loaned the Company an aggregate principal amount of $150,000 AUD. The Company intends to use the net proceeds therefrom for general working capital purposes.

The maturity date of the Loan is November 1, 2024, or sooner at the discretion of the Company, and the Loan bears an interest rate of twelve percent (12%) per annum. The Company has the right to prepay in full at any time with no prepayment penalty.

The foregoing description of the Loan do not purport to be complete and are qualified in their entirety by reference to the full text of each of the Loan, which is filed as Exhibit 4.1 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated herein by reference.